Hypogonadism in males with chronic kidney disease: Another cause of resistance to erythropoiesis-stimulating agents

Contributions to Nephrology

Volumn 178, Issue , 2012, Pages 35-39

  Stenvinkel, Peter ^a,b   Bárány, Peter ^a  

^a Divisions of Baxter Novum and Renal Medicine   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862125179     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000337796     Document Type: Article

References (38)

1. Carrero JJ, Qureshi AR, Nakashima A, et al: Prevalence and clinical implications of testosterone deficiency in men with end- stage renal disease. Nephrol Dial Transplant 2011;26:184- 190.
2. Carrero JJ, Qureshi AR, Parini P, et al: Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613- 620.
3. Yilmaz MI, Sonmez A, Qureshi AR, et al: Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol 2011;6:1617- 1625.
4. Carrero JJ, Kyriazis J, Sonmez A, et al: Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol 2012;7:207- 215.
5. Solomon SD, Uno H, Lewis EF, et al: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146- 1155.
6. Barany P, Divino-Filho JC, Bergström J: High C- reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565- 568.
7. Elliott J, Mishler D, Agarwal R: Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2010;16:94- 100.
8. Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger H, et al: Testosterone deficiency is a cause of anemia and reduced responsiveness to erythropoiesis stimulating agents in men with chronic kidney disease. Nephrol Dial Transpl 2012;27:709- 715.
9. Thomas K: On a new observation on the hematotrophic effect of testosterone derivatives. Klin Wochenschr 1961;39:55- 56.
10. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, et al: Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 2006;166:1380- 1388.
11. Waalen J, von Lohneysen K, Lee P, Xu X, Friedman JS: Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in a large cohort of elderly individuals with anaemia of known and unknown cause. Eur J Haematol 2011;87:107- 116.
12. Fernandez-Balsells MM, Murad MH, Lane M, et al: Clinical review. 1. Adverse effects of testosterone therapy in adult men: a systematic review and meta- analysis. J Clin Endocrinol Metab 2010;95:2560- 2575.
13. Fonseca R, Rajkumar SV, White WL, Tefferi A, Hoagland HC: Anemia after orchiectomy. Am J Hematol 1998;59:230- 233.
14. Mirand EA, Gordon AS, Wenig J: Mechanism of testosterone action in erythropoiesis. Nat Genet 1965;206:270- 272.
15. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S: Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008;93:914- 919.
16. Kim SW, Hwang JH, Cheon JM, et al: Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. J Korean Med Sci 2005;20:409- 416.
17. Bachman E, Feng R, Travison T, et al: Testosterone suppresses hepcidin in men: a potential mechanism for testosterone- induced erythrocytosis. J Clin Endocrinol Metab 2010;95:4743- 4747.
18. Nemeth E, Rivera S, Gabayan V, et al: IL- 6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271- 1276.
19. Coyne DW: Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011;80:240- 244.
20. Richardson JR Jr, Weinstein MB: Erythropoietic response of dialyzed patients to testosterone administration. Ann Intern Med 1970;73:403- 407.
21. Gaughan WJ, Liss KA, Dunn SR, et al: A 6- month study of low- dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997;30:495- 500.
22. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ: Androgens potentiate the effects of erythropoietin in the treatment of anemia of end- stage renal disease. Am J Kidney Dis 1991;17:29- 33.
23. Lee MS, Ahn SH, Song JH: Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low- dose recombinant human erythropoietin. Korean J Intern Med 2002;17:167- 173.
24. DeLong M, Logan JL, Yong KC, Lien YH: Renin- angiotensin blockade reduces serum free testosterone in middle- aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant 2005;20:585- 590.
25. Grossmann M, Panagiotopolous S, Sharpe K, et al: Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 2009;70:547- 553.
26. Haurani FI, Green D: Primary defective iron reutilization. Response to testosterone therapy. Am J Med 1967;42:151- 158.
27. Schustack A, Meshiaj D, Waiss Z, Gotloib L: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow- up of up to 8 years on 16 patients. Clin Nephrol 1985;23:303- 306.
28. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F: Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double- blinded placebo- controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602- 612.
29. Almeida OP, Yeap BB, Hankey GJ, Jamrozik K, Flicker L: Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 2008;65:283- 289.
30. Yeap BB, Almeida OP, Hyde Z, Chubb SA, Hankey GJ, Jamrozik K, et al: Higher serum free testosterone is associated with better cognitive function in older men, while total testosterone is not. The Health In Men Study. Clin Endocrinol (Oxf) 2008;68:404- 412.
31. Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA, et al: Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006;91:3908- 3915.
32. Malkin CJ, Jones TH, Channer KS: The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007;9:44- 50.
33. Malkin CJ, Jones RD, Jones TH, Channer KS: Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 2006;111:265- 274.
34. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al: Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc 2010;58:1134- 1143.
35. Wehr E, Pilz S, Boehm BO, Marz W, Obermayer-Pietsch B: Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 2010;73:243- 248.
36. Nimptsch K, Platz EA, Willett WC, Giovannucci E: Association between plasma 25- OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf) 2012 Jan 2. doi: 10.1111/j.1365- 2265.2012.04332.x. [Epub ahead of print].
37. Lee DM, Tajar A, Pye SR, et al: Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol 2012;166:77- 85.
38. Pilz S, Frisch S, Koertke H, et al: Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res 2011;43:223- 225.